About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 11279 record(s)
Req # A-2024-000202
Any communications from Cannabis and Controlled Substances Branch to third parties questioning whether a cannabis product with a brand element or brand name or product name containing the word "Hi-Def" may be considered dried cannabis or another form of cannabis under the Cannabis Act or its regulations or violate any related promotion or packaging or labelling laws.Organization: Health Canada
May 2024
Req # A-2020-001326
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-112741-953.Organization: Health Canada
May 2024
Req # A-2020-001891
Adverse Drug Reactions (ADRs) for Pantoprazole sodium. Report numbers: E2B_03353411, E2B_03373956. ADRs for Tecta. Report numbers: E2B_03380105, E2B_03402109. ADRs for Pantoprazole magnesium. Report numbers: 921752, E2B_03380218. ADRs for Amphetamine aspartate monohydrate/ amphetamine sulfate/ dextroamphetamine saccharate/ dextroamphetamine sulfate. Report numbers: E2B_03355369, 921791, E2B_03385512.Organization: Health Canada
May 2024
Req # A-2021-001088
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-106818-522.Organization: Health Canada
May 2024
Req # A-2021-001202
Adverse Drug Reactions (ADRs). Report numbers: E2B_03487061, E2B_03487072, E2B_03487074, E2B_03487077, E2B_03490042, E2B_03490043, E2B_03490045, E2B_03490049, E2B_03490050, E2B_03491975, E2B_03492634, E2B_03492652, E2B_03495037, E2B_03524901, E2B_03542686, E2B_03606495, E2B_03614104, E2B_03622423, E2B_03638865, E2B_03867292.Organization: Health Canada
May 2024
Req # A-2021-001291
Adverse Drug Reactions (ADRs). Report numbers: 000923457, E2B_03206897, 000938466, 000949183, 000956295, E2B_03838745, E2B_03998278, E2B_03081668, E2B_03840368, E2B_03940910, E2B_02771636, E2B_02836652, E2B_02836886, E2B_03503549, E2B_02758454, E2B_03320166, 000927161, 000721376, E2B_01656713, E2B_02461795.Organization: Health Canada
May 2024
Req # A-2022-001452
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 22-075408-992, Deputy Ministerial Meeting with DNAStack.Organization: Health Canada
May 2024
Req # A-2022-001617
Adverse Drug Reaction (ADR). Report number: 001025337Organization: Health Canada
May 2024
Req # A-2023-000321
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-102577-832.Organization: Health Canada
May 2024
Req # A-2023-000751
Adverse Drug Reactions (ADRs) for ONDANSETRON. Report numbers: 001043963, E2B_06419945, E2B_06428933, E2B_06445688. ADRs for PANTOPRAZOLE SODIUM. Report numbers: E2B_06417696, E2B_06464904, E2B_06416475. ADR for GUANFACINE. Report number: E2B_06450662.Organization: Health Canada
May 2024